Tech Company Financing Transactions
Adaptive Biotechnologies Funding Round
Adaptive Biotechnologies secured a $195 million financing round on 5/6/2015. Investors included Matrix Capital Management, Alexandria Venture Investments and Casdin Capital.
Transaction Overview
Company Name
Announced On
5/6/2015
Transaction Type
Venture Equity
Amount
$195,000,000
Round
Undisclosed
Investors
Proceeds Purpose
This investment will fuel significant expansion of the Company's research platform, support the commercialization of a novel target identification technology for T-cell therapy, and expedite global regulatory submissions and launch timelines for its research-use-only and clinical diagnostic products. Additionally, funds will be allocated to support the continued growth of the world's largest database of adaptive immune receptors to inform future diagnostic and therapeutic discoveries across disease states.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1551 Eastlake Ave. East 200
Seattle, WA 98102
USA
Seattle, WA 98102
USA
Phone
Website
Email Address
Overview
Adaptive (Nasdaq: ADPT) is at the forefront of immune-based discoveries, combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 5/6/2015: Moximed venture capital transaction
Next: 5/6/2015: DrFirst venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs